N-去甲盐酸多塞平
N-去甲盐酸多塞平结构式
|
常用名 | N-去甲盐酸多塞平 | 英文名 | nordoxepin |
|---|---|---|---|---|
| CAS号 | 2887-91-4 | 分子量 | 265.350 | |
| 密度 | 1.1±0.1 g/cm3 | 沸点 | 420.8±44.0 °C at 760 mmHg | |
| 分子式 | C18H20ClNO | 熔点 | 159-160ºC | |
| MSDS | 中文版 美版 | 闪点 | 174.5±17.9 °C | |
| 符号 |
GHS07, GHS09 |
信号词 | Warning |
|
Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 877(27) , 3025-30, (2009) Perhexiline is a drug that is used for treatment of moderate to severe angina pectoris that has not responded to other treatment. It has a low therapeutic index, and saturable metabolism that is also subject to genetic polymorphism (CYP2D6). Concentration mon... |
|
|
Simultaneous determination of doxepin and nordoxepin in serum using high-performance liquid chromatography.
J. Chromatogr. A. 419 , 445-51, (1987)
|
|
|
Quantitative determination of E- and Z-doxepin and E- and Z-desmethyldoxepin by high-performance liquid chromatography.
Ther. Drug Monit. 17(4) , 371-6, (1995) A high-performance liquid chromatographic (HPLC) method was developed for the quantitative, simultaneous determination of the following four compounds in serum: E-doxepin, Z-doxepin, E-desmethyldoxepin, and Z-desmethyldoxepin. A 3-microns analytical silica co... |
|
|
Bioequivalence: issues and options.
J. Pharmacokinet. Biopharm. 25(6) , 743-52, (1997)
|
|
|
Doxepin and nordoxepin concentrations in body fluids and tissues in doxepin associated deaths.
Forensic Sci. Int. 190(1-3) , 74-9, (2009) Body fluids and tissues in eight doxepin (Dox)-related deaths were investigated in order to prove whether the individual concentration of Dox, the concentration sum of parent drug and its active metabolite N-desmethyldoxepin (NDox) or the concentration ratio ... |
|
|
Detection of doxepin and its major metabolite desmethyldoxepin in hair following drug therapy.
J. Anal. Toxicol. 22(6) , 531-6, (1998) Doxepin is a tricyclic antidepressant that is widely prescribed for the treatment of mild depression. In this study, hair samples collected from a patient receiving 25 mg of doxepin daily were analyzed. Doxepin was administered to the patient for 4 months (Ju... |
|
|
Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration.
J. Clin. Pharmacol. 43(10) , 1149-57, (2003) A novel diltiazem HCl extended-release (ER) tablet formulation was developed for evening administration in the management of angina and hypertension. Pharmacokinetics of the formulation were evaluated to identify variations in morning (7 a.m. or 8 a.m.) versu... |
|
|
Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach.
Eur. J. Clin. Pharmacol. 58(4) , 253-7, (2002) Little information on the population pharmacokinetics of the tricyclic antidepressant doxepine and its pharmacologically active metabolite desmethyldoxepine is available. However, a more individualised drug therapy may be feasible if the influence of various ... |
|
|
The isomeric metabolites of doxepin in equine serum and urine.
J. Pharm. Biomed. Anal. 29(1-2) , 317-23, (2002) Due to its tranquilizing properties, the tricyclic antidepressant doxepin may be misused as a doping agent in competition horses. Therefore, efficient analytical procedures are required to detect this drug in samples submitted for doping control. To screen fo... |
|
|
Doxepin concentrations in plasma and cerebrospinal fluid.
J. Neural Transm. Gen. Sect. 118(4) , 641-5, (2011) Doxepin--like other antidepressant drugs (ADs)--shows a variable antidepressant effect in clinical practice. The cause for this variability is as yet unclear; however, pharmacokinetic factors such as the variable permeability of doxepin into the cerebrospinal... |